Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Matrix metalloproteinase inhibitors.

P D Brown1

  • 1Department of Clinical Research, British Biotech Pharmaceuticals Ltd, Oxford, UK.

Breast Cancer Research and Treatment
|March 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.

Neuro-oncology·2025
Same author

Distribution of virulence determinants among antimicrobial-resistant and antimicrobial-susceptible <i>Escherichia coli</i> implicated in urinary tract infections.

Indian journal of medical microbiology·2016
Same author

Growth of single-layer boron nitride dome-shaped nanostructures catalysed by iron clusters.

Nanoscale·2016
Same author

Ag-catalysed cutting of multi-walled carbon nanotubes.

Nanotechnology·2016
Same author

Beta Cell Regenerating Potential of <i>Azadirachta indica</i> (Neem) Extract in Diabetic Rats.

The West Indian medical journal·2015
Same journal

Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

Breast cancer research and treatment·2026
Same journal

Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy.

Breast cancer research and treatment·2026
Same journal

Discrimination, spectrum, and clinical utility: ICG lymphography drainage time in axillary staging.

Breast cancer research and treatment·2026
Same journal

Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.

Breast cancer research and treatment·2026
Same journal

Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.

Breast cancer research and treatment·2026
Same journal

Subjective socioeconomic status moderates the relationship between objective neighborhood disadvantage and quality of life in middle- and older-aged women with breast cancer.

Breast cancer research and treatment·2026
See all related articles

Matrix metalloproteinase (MMP) inhibitors show promise in slowing cancer growth and metastasis. Clinical trials are underway to evaluate their effectiveness in complementing existing cancer treatments and improving survival rates.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Matrix metalloproteinases (MMPs) are enzymes crucial for tissue remodeling, growth, and repair.
  • Elevated MMP levels, particularly stromelysin-3 and gelatinase, are observed in tumor-associated stroma, suggesting a role in cancer progression.
  • MMPs facilitate local tumor invasion and metastasis.

Purpose of the Study:

  • To investigate the therapeutic potential of synthetic matrix metalloproteinase (MMP) inhibitors in cancer treatment.
  • To evaluate the efficacy of MMP inhibitors in preclinical cancer models, specifically breast cancer.
  • To assess the early clinical outcomes of MMP inhibitors in patients with advanced malignancy.

Main Methods:

  • Development of synthetic low molecular weight MMP inhibitors, including peptide-based and non-peptide based compounds.

Related Experiment Videos

  • Testing MMP inhibitors in preclinical breast cancer models to assess their impact on primary and secondary tumor growth and metastasis.
  • Initiation of clinical trials to evaluate MMP inhibitors in patients with advanced cancers.

    • Main Results:

    • MMP inhibitors demonstrated significant reduction in primary and secondary tumor growth rates in breast cancer models.
    • MMP inhibitors effectively blocked tumor metastasis in preclinical studies.
    • Early clinical trial results suggest MMP inhibitors may slow tumor growth, though not optimal for tumoristatic effects.

    Conclusions:

    • Synthetic MMP inhibitors show significant potential as anticancer agents by targeting tumor invasion and metastasis.
    • Further clinical trials, particularly in the adjuvant setting, are essential to determine the full therapeutic value of MMP inhibitors.
    • MMP inhibitors may serve as a valuable adjunct to existing cancer therapies, potentially prolonging survival.